Human papillomavirus vaccine and pregnancy

Canadian Family Physician

Volumn 58, Issue 3, 2012, Pages 268-269

  Narducci, Andrea ^b   Einarson, Adrienne ^a   Bozzo, Pina ^a  

^a Motherisk Program   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DRUG SAFETY; GESTATIONAL AGE; HUMAN; IMMUNIZATION; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; SHORT SURVEY;

EID: 84858315110     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 2008;23(3):709-15. Epub 2008 Jan 8.
2. Hermonat PL, Kechelava S, Lowery CL, Korourian S. Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception. Hum Pathol 1998;29(2):170-4. (Pubitemid 28099513)
3. Puranen M, Yliskoski M, Saarikoski S, Syrjanen K, Syrjanen S. Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 1996;174(2):694-9. (Pubitemid 26070167)
4. Public Health Agency of Canada [website]. Statement on human papillomavirus vaccine. Ottawa, ON: Public Health Agency of Canada; 2007. Available from: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-02/indexeng. php. Accessed 2011 Oct 4.
5. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114(6):1179-88.
6. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114(6):1170-8.
7. Merck & Co. Merck pregnancy registry program. Fourth annual report on exposure during pregnancy from the Merck pregnancy registry for quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine [GARDASIL/ SILGARD] covering the period from first approval (June 1, 2006) through May 31, 2010. North Wales, PA: Merck & Co. In press.
8. Cervarix [product monograph]. Mississauga, ON: GlaxoSmithKline; 2011.
9. Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712. DOI: 10.1136/bmj.c712.